Equities Analysts Offer Predictions for CRBU FY2025 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Caribou Biosciences in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski expects that the company will post earnings per share of ($1.31) for the year. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The firm had revenue of $2.02 million during the quarter, compared to the consensus estimate of $3.37 million.

A number of other research firms have also weighed in on CRBU. Citigroup lowered their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 26th. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a research report on Friday, November 15th. Finally, Bank of America cut their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $10.33.

Caribou Biosciences Stock Performance

Shares of CRBU stock opened at $1.52 on Thursday. Caribou Biosciences has a twelve month low of $1.47 and a twelve month high of $8.33. The stock has a fifty day simple moving average of $1.84 and a two-hundred day simple moving average of $1.99. The stock has a market capitalization of $137.64 million, a price-to-earnings ratio of -0.92 and a beta of 2.34.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CRBU. PFM Health Sciences LP boosted its stake in Caribou Biosciences by 5.5% in the third quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after acquiring an additional 223,299 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Caribou Biosciences by 25.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock valued at $4,302,000 after purchasing an additional 536,162 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Caribou Biosciences by 6.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock worth $3,980,000 after purchasing an additional 124,782 shares in the last quarter. FMR LLC grew its stake in Caribou Biosciences by 7.4% during the 3rd quarter. FMR LLC now owns 1,581,493 shares of the company’s stock worth $3,100,000 after buying an additional 109,606 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in Caribou Biosciences during the 2nd quarter valued at about $2,432,000. Hedge funds and other institutional investors own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.